Sign in
WithdrawnNo phase

Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease

Key facts

Who runs it
C2N Diagnostics
Trial code
Status
Withdrawn
Started
Jul 2025
Expected to end
Mar 2028
Type of study
Interventional, 2 groups
Treatments tested
  • PrecivityAD2 - Early Testing
  • PrecivityAD2 - Delayed Testing
Record updated
16 December 2025
Why it stopped
sponsor decision to cancel project before enrollment.

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Minimum age: 50 years
  • Patients presenting with symptoms of mild cognitive impairment (MCI) or other cognitive impairments in which the enrolling clinician clinically suspects Alzheimer's pathology as the primary cause of symptomatic presentation
  • Patients presenting with mixed brain pathologies including MCI/ cognitive impairments in which the investigator clinically suspects Alzheimer's pathology as the primary or contributing cause of symptomatic presentation
  • Patients are able to attend study visits and standard care visits over the period of 1 year from the date of enrollment
  • Patients are able to undergo routine phlebotomy and provide up to six (6) 10 ml tube(s) of blood for study related tests plus any additional blood necessary for standard laboratory testing at each study timepoint
  • Patients are able to undergo standard care diagnostic procedures to include MRI (or CT), amyloid PET and/or CSF biomarker testing for AD diagnosis if prescribed by investigator
  • Patients are able to provide informed consent. Or, if in the opinion of the clinician, the patient is unable to adequately understand the nature of the trial and protocol requirements, a family member or appropriate representative of the patient is present to consent, with additional assent by the patient

Who cannot take part

  • Patients previously diagnosed with AD, unless the ADELAIDE investigator has a strong clinical suspicion suggestive of an incorrect initial diagnosis upon referral
  • Patients being evaluated for cognitive impairment known to be predominantly the result of a disease or condition other than AD
  • Patients with no cognitive impairment or clinical symptoms of AD
  • Patients desiring genetic testing for Alzheimer's disease markers without current cognitive impairment or other relevant clinical symptoms
  • Patients younger than 50 years of age
  • Patients who are not able or not willing to undergo standard care diagnostic procedures to include MRI (or CT), amyloid PET and/or CSF biomarker testing for AD diagnosis as prescribed by investigator
  • Patients who are not able to understand the nature of the study nor the study requirements and not represented by a family member or other appropriate representative who is able to consent on behalf of the patient
  • Patients who are not able to commit to attending the required study and/or standard care visits
  • Patients who are not able to undergo routine phlebotomy or provide blood samples in the quantity required by the study protocol

About the trial

What the trial wants to find out

The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or non-Alzheimer's diagnosis as compared to delayed result disclosure.

Read full original descriptionShow less

Participants will be randomized into the early PrecivityAD2 blood biomarker test \& disclosure group (Cohort A) or to the later PrecivityAD2 blood biomarker test \& disclosure group (Cohort B) where blood samples will be collected and tested using the PrecivityAD2 test at Visit 1 (day 0) and Visit 2 (day 90). Participants will attend study visits for one year after their enrollment. An optional sub-study will be offered to collect information through questionnaires at each visit regarding participant's and their care-giver's experiences through the AD diagnostic journey.

The 2 groups in the trial

  • Early Testing Group (Cohort A)Treatment being tested

    Participants in this group will have blood drawn from the PrecivityAD2 test at Visit 1 (Day 0). Physicians will use these results in clinical decision-making from that point forward.

    Treatment: PrecivityAD2 - Early Testing

  • Delayed Testing Group (Cohort B)Treatment being tested

    Participants in this group will have blood drawn for the PrecivityAD2 test at Visit 2 (Day 90). Until then, standard clinical decision-making will process without access to PrecivityAD2 results.

    Treatment: PrecivityAD2 - Delayed Testing

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Study of the Clinical Effect of the Implementation of a Blood Biomarker Into Memory Clinics in the Department of Veterans Affairs and Other Closed System Healthcare Memory and Dementia Sites in the United States
Record updated
16 December 2025